18:46 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Barvarian Nordic's smallpox vaccine meets in Phase III

Bavarian Nordic A/S (CSE:BAVA) reported data from an open-label Phase III trial showing that its Imvamune smallpox vaccine met the co-primary endpoints of non-inferiority to ACAM2000, an FDA-approved, second-generation smallpox vaccine from Emergent BioSolutions Inc....
00:26 , Jul 21, 2017 |  BC Week In Review  |  Company News

Emergent buys Sanofi smallpox vaccine

Infectious disease company Emergent BioSolutions Inc. (NYSE:EBS) said it purchased second-generation smallpox vaccine ACAM2000 from Sanofi (Euronext:SAN; NYSE:SNY) for $97.5 million in cash upfront and up to $27.5 million in near-term regulatory and manufacturing-related milestones....
01:01 , Apr 28, 2017 |  BC Innovations  |  Finance

1Q17 public-private partnership roundup

This quarter’s deal-making in public-private partnerships (PPPs) picked up from the slow rate in the second half of last year, with 1Q17 activity comparable to that seen at the start of last year. Led by...
20:01 , Dec 6, 2016 |  BC Week In Review  |  Clinical News

Imvamune: Ph III started

Bavarian Nordic said the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) completed enrollment of 440 subjects in a Phase III trial comparing Imvamune vs. ACAM2000, an FDA-approved, second-generation smallpox vaccine. The trial enrolled...
07:00 , Sep 12, 2011 |  BioCentury  |  Politics, Policy & Law

Biodefense report card

Ten years after 9/11 and the subsequent anthrax attacks alerted America to the threat posed by bioterrorism, progress in developing and procuring vaccines and drugs to protect the civilian population has been frustratingly slow. An...
08:00 , Mar 2, 2009 |  BC Week In Review  |  Clinical News

Siga preclinical data

In monkeys, ST-246 in combination with ACAM2000 reduced the size and intensity of the lesion formed at the vaccine administration site. The compound/vaccine combination had levels of protection similar to vaccine alone in monkeys...
07:00 , Aug 4, 2008 |  BioCentury  |  Finance

Acambis chronicles

Acambis chronicles From its five-year high of 393p on Sept. 15, 2003, through July 25 of this year, Acambis (LSE:ACM) has lost 70% of its value. The stock jumped 60% to 185.5p on July 28 after...
07:00 , Aug 4, 2008 |  BioCentury  |  Finance

Ebb & Flow

Lilly’s project finance Eli Lilly (NYSE:LLY) pulled a play from the biotech book when it did a deal with hedge fund TPG-Axon and Quintiles’ NovaQuest unit for $300 million in funding to conduct trials of its...
07:00 , Jul 28, 2008 |  BC Week In Review  |  Company News

Acambis, sanofi-aventis deal

sanofi-aventis will acquire vaccine company Acambis for 190p per share or about £276 million ($553 million) in cash. The price is a 64% premium to Acambis’ close of 116p on July 25, before the deal...
07:00 , Jul 28, 2008 |  BioCentury  |  Finance

Ebb & Flow

For the second time this month, a sizeable first-time fund with a seasoned team has closed above its initial target. Last week, Cowen Healthcare Royalty Partners closed its first fund at more than $500 million. In...